4 results
To determine whether administration of exogenous surfactant using a minimally-invasive technique improves outcome in preterm infants 25-28 weeks gestation treated with continuous positive airway pressure (CPAP).
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.
Proof of Principle: to assess feasibility to measure; (1) a reproducible 1st thermal IDC, (2) at least 1 recirculation IDC using the FBG photonic sensor both peripheral and nasal. - to compare the acquired Stroke Volume (SV) and Cardiac Output (CO)…